Lack of Postmortem Facilities: Calcutta HC directs Centre to bring AIIMS Kalyani at par with Delhi AIIMS

Kolkata: When heard about the lack of a postmortem facility at a premier institute like All India Institute of Medical Sciences (AIIMS) Kalyani, the Calcutta High Court conveyed its astonishment and directed the Centre to enhance the infrastructure of AIIMS Kalyani in West Bengal to match that of AIIMS in Delhi by December 2025.

During the hearing session, a bench of Justice Tirthankar Ghosh observed, “This is surprising that till date there is no infrastructure for conducting post-mortem examination at AIIMS, Kalyani and the infrastructure of a tertiary referral hospital like J.N.M. Hospital, Kalyani had to be used for post mortem examination by the doctors of AIIMS, Kalyani.” 

The court was hearing a matter concerning the rape and murder of a schoolgirl in West Bengal’s Jayanagar. The high court was told that AIIMS Kalyani lacked the infrastructure to carry out a post-mortem, following which the examination had to be conducted in another nearby hospital.  

Also read- Allegations of Threat Culture’ in Bengal medical colleges: Calcutta HC directs Govt to file affidavit

“The word “All India Institute of Medical Sciences” refers to a premier brand health organisation, where a common man can have the services of the best of the doctors available in the Country. The institute is not restricted only to academic purposes but also to rendering services to patients who are suffering from acute diseases. If an AIIMS is situated within a State the common man at large should be benefited by the services of the best of the doctors who are ready, but they are not having a support system to execute their ability,” stated the court as quoted by ABP Live news report.  

Further, it added, “The institution has been offering courses to best of the students across the Country at the Graduation and Post-graduation level in the field of medical sciences. So far as the services to the citizen at large are concerned, the confidence must be reposed that every infrastructure and facility is made available within the boundary and premises of AIIMS, Kalyani.”

The court termed the information as disheartening and surprising. Later, it directed the Secretary of the Ministry of Health and Family Welfare, Government of India, to evaluate the deficiencies in infrastructure at AIIMS, Kalyani, ensuring that the facilities are developed to match those of AIIMS, Delhi, or AIIMS, Rishikesh.

“Steps be taken by the Ministry of Health and Family Welfare, Government of India to complete the infrastructure preferably by 31st December 2025. In case any permission, license is to be granted by the State Government no deterrence or hindrance be created in granting of such license to the authorities of AIIMS, Kalyani. The State would cooperate for facilitating the services of AIIMS, Kalyani to the common people at large.”

Also read- Ex-colleague moves HC seeking ED probe into alleged financial irregularities by Former RG Kar Principal

Powered by WPeMatico

The 50 by 50 goal: Report explores how to reduce probability of dying before age 70 by 50% globally by 2050

A team of 50 leading international experts, The Lancet Commission on Investing in Health (CIH), explored this question, resulting in clear, actionable, and achievable measures for achieving this ambitious goal worldwide.

Powered by WPeMatico

Evidence builds for near infrared light treatment in traumatic brain injury

Birmingham scientists have shown light therapy delivered transcranially (through the skull) can aid tissue repair after mild traumatic brain injury (mTBI).

Powered by WPeMatico

Study identifies genetic factors crucial in acute myeloid leukemia survival for Black patients

Researchers have led a global study that identified molecular predictors of survival among Black patients with acute myeloid leukemia (AML). The study suggests a need to modify current AML risk layers by including ancestry-specific genetic factors and testing those in clinical trials.

Powered by WPeMatico

Framework reveals how neglecting income, education and ethnicity affects disease spread predictions on COVID-19 data

An international team of researchers have developed an innovative approach to epidemic modeling that could transform how scientists and policymakers predict the spread of infectious diseases. Led by Dr. Nicola Perra, Reader in Applied Mathematics, the study published in Science Advances introduces a new framework that incorporates socioeconomic status (SES) factors—such as income, education, and ethnicity—into epidemic models.

Powered by WPeMatico

How much do so-called ‘health foods’ really contribute to nutrient intake?

A research group led by Professor Keiko Asakura and Assistant Professor Minami Sugimoto of the Faculty of Medicine at Toho University analyzed dietary intake data of the Japanese population collected in 2012. They assessed the contribution of so-called “health foods” (fortified foods and dietary supplements) to nutrient intake. This study is expected to be useful for the formulation of health policies aimed at improving nutrient intake in Japan.

Powered by WPeMatico

Zydus receives USFDA nod for Paliperidone ER Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg

Ahmedabad: Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9
mg (USRLD: Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg).

Paliperidone extended-release tablets are indicated for the acute and maintenance treatment of
schizophrenia, acute treatment of schizoaffective disorder as monotherapy and acute treatment
of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants.
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at
SEZ, Ahmedabad.

Read Also: Zydus Lifesciences bags tentative USFDA nod for Enzalutamide Tablets for prostate cancer

Paliperidone extended-release tablets had annual sales of USD XXX 47.1 in the United States
(IQVIA MAT July 2024).

The group now has 400 approvals and has so far filed over 465* ANDAs since the
commencement of the filing process in FY 2003-04.

Read Also: USFDA issues EIR for Zydus Lifesciences Pharmez transdermal patch manufacturing facility

Powered by WPeMatico

AIIMS specifies feeder qualifications for 72 DM, MCh courses

New Delhi: For super-specialisation in 72 DM and MCh courses across Institutes of National Importance (INI), the All India Institute of Medical Sciences (AIIMS) has notified the feeder qualifications for the INI SS January 2025 session.

Laying down the eligibility criteria in its prospectus for the Institute of National Importance Super-Speciality Entrance Test (INI SS) January 2025 session, the AIIMS detailed the prior/required or feeder qualifications for DM, MCh and MD Hospital administration courses. 

Institute of National Importance Super-Specialty Entrance Test (INI-SS)- The entrance test for admission into DM/M.Ch./MD Hospital Administration Courses at Institutes of National Importance (INI) for Medical Education namely, AIIMS-New Delhi and all new AIIMS, JIPMER-Puducherry, PGIMER-Chandigarh, NIMHANS-Bengaluru and Sree Chitra Tirunal Institute for Medical Sciences & Technology- Trivandrum is held twice in a year for January and July session of respective year. 

Feeder Qualifications:

All candidates who are vying for admission in DM and MCh courses at INIs are advised to take note of the following details: 

DM Courses Eligibility and Educational Qualification

S.No Institute Name Required Qualification
1. DM- ACUTE CARE-EMERGENCY MEDICINE(MS0701701)
(I) PGIMER MD Internal Medicine/General Medicine/ Emergency Medicine or Equivalent
2. DM-ADDICTION PSYCHIATRY(MS0705601)
(I) AIIMS M.D./DNB in Psychiatry of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER
(III) NIMHANS
3.DM-CARDIAC SURGICAL INTENSIVE CARE(MS0701002)HIATRY(MS0705601)
(I) AIIMS MD/DNB in Anaesthesia/Pediatrics/Medicine of this Institute or any other University or equivalent degree recognized by the NMC
4. DM-CARDIAC-ANAESTHESIA AND CRITICAL CARE/DM-CARDIOTHORACIC & VASCULAR ANESTHESIA*/Cardiac Anaesthesia & Intensive Care**/CTVS Anaesthesiology (MS0700801)
(I) AIIMS M.D/ DNB in Anaesthesiology of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER**
(III) SCTIMST*
(Iv) JIPMER
5.DM-CARDIOLOGY(MS0700901)
(I) AIIMS M.D/DNB in Medicine/Pediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) SCTIMST M.D/DNB in General Medicine/Pediatrics of any Indian University or equivalent degree recognized by the NMC
(III) PGIMER MD in Medicine or equivalent
(Iv) JIPMER M.D/ DNB Degree in General Medicine / Pediatrics/ Pulmonary Medicine recognized by the NMC.
6.DM-CARDIOVASCULAR RADIOLOGY & ENDOVASCULAR INTERVENTIONS/DM-CARDIOVASCULAR IMAGING AND VASCULAR INTERVENTIONAL RADIOLOGY*(MS0701101)
(I) AIIMS M.D /DNB in Radio-Diagnosis or equivalent degree
(II) SCTIMST
(III) PGIMER M.D /DNB in Radio-Diagnosis/Radiology of any Indian University or equivalent degree recognized by the NMC
7.DM-CHILD AND ADOLESCENT PSYCHIATRY(MS0705602)
(I) PGIMER MD/DNB Psychiatry or equivalent
(II) NIMHANS
8.DM- CLINICAL HEMATOLOGY(MS0702501)
(I) AIIMS M.D/ DNB in Medicine/Pediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER MD Medicine or equivalent
9.DM-CLINICAL IMMUNOLOGY & RHEUMATOLOGY(MS0707201)
(I) AIIMS MD Medicine, MD Pediatrics
(II) PGIMER MD Medicine or equivalent
(III) JIPMER MD/DNB General Medicine/Pediatrics
10. DM-CLINICAL PHARMACOLOGY(MS0705201)
(I) AIIMS M.D/DNB in Medicine/Pharmacology/Pediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER MD Pharmacology or equivale
(III) JIPMER
11. DM-CRITICAL CARE MEDICINE/CRITICAL CARE*/DM-INTENSIVE CARE**(MS0700101)
(I) AIIMS M.D. in Anaesthesiology/Medicine/Chest Medicine of this Institute or any other University or equivalent degree recognized by the NMC
(II) JIPMER* M.D. in Anaesthesiology/ General Medicine/Pulmonary Medicine of this Institute or any other University or equivalent degree recognized by the NMC
(III) PGIMER** MD Anaesthesia/Internal Medicine or equivalent
12. DM-ENDOCRINOLOGY(MS0701901)
(I) AIIMS M.D./ DNB Degree in Medicine/Pediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) JIPMER M.D./ DNB Degree in General Medicine/Pediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(III) PGIMER MD Medicine or equivalent
13. DM- FORENSIC PATHOLOGY/ (MS0702102)
(I) AIIMS MD/DNB Forensic Medicine/Forensic Medicine and Toxicology recognized by Medical Council of India/NMC
14. DM-FORENSIC PSYCHIATRY(MS0705603)
(I) NIMHANS MD/DNB in Psychiatry
15. DM-FORENSIC RADIOLOGY & VIRTUAL AUTOPSY(MS0702103)
(I) AIIMS MD/DNB Forensic Medicine/Forensic Medicine and Toxicology recognized by Medical Council of India/NMC
16. DM-GASTROENTEROLOGY/MEDICAL GASTROENTEROLOGY* (MS0702201)
(I) AIIMS M.D/ DNB in Medicine of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER MD Medicine or equivalent
(III) JIPMER* M.D/ DNB in General Medicine /Pediatrics of this Institute or any other University or equivalent degree recognized by the NMC
17. DM-HEMATOPATHOLOGY(MS0702502)
(I) AIIMS M.D/DNB in Pathology/Lab. Medicine of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER MD Pathology or equivalent
18. DM-HEPATOLOGY(MS0702202)
PGIMER MD Medicine/Pediatrics or equivalent
19. DM- HIGH ALTITUDE MEDICINE (MS0705401)
(I) AIIMS MD/DNB Internal Medicine/Physiology/Anaesthesia/Community Medicine recognized by Medical Council of India
20. DM-HISTOPATHOLOGY(MS0705102)
(I) PGIMER MD Pathology or equivalent
21. DM-HOSPITAL MEDICINE & CRITICAL CARE (MS0708001)
(I) AIIMS MD in Internal Medicine, Geriatric Medicine
22. DM-INFECTIOUS DISEASES/ CLINICAL INFECTIOUS DISEASES ( MS0702701)
(I) AIIMS M.D/DNB in Medicine/Pediatrics/Microbiology/Tropical Medicine of this Institute or any other University or equivalent degree recognized bythe NMC
(II) AIIMS (Raipur) M.D/DNB in General Medicine/Pediatrics /Tropical Medicine or an equivalent qualification as recognized by Medical Council of India/NMC
(III) PGIMER MD/DNB is internal/General medicine
23. DM-INTERVENTIONAL RADIOLOGY(MS0705801)
(I) AIIMS MD/DNB (Radiology/Radio diagnosis) recognized by MCI/NMC
(II) PGIMER MD/DNB in Radio-diagnosis or equivalent
24. DM-MEDICAL AND FORENSIC TOXICOLOGY (MS0702101)
(I) AIIMS MD/DNB In forensic Medicine or forensic Medicine &Toxicology/Pharmacology/Emergency Medicine/Internal/General Medicine/Paediatrics recognized by Medical Council of India/ NMC
25. DM-MEDICAL GENETICS(MS0704901)
(I) AIIMS MD in Paediatrics/Medicine/Obstetrics and Gynaecology of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER MD Paediatrics or equivalent
26. DM-MEDICAL ONCOLOGY(MS0702901)
(I) AIIMS M.D/DNB in Medicine/Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER
(III) JIPMER M.D. / DNB Degree in Medicine / Pediatrics /Radiotherapy recognized by the Medical Council of India.
27. DM-NEONATOLOGY(MS0704902)
(I) AIIMS M.D Degree in Paediatrics of this Institute or any other University or (II) PGIMER equivalent degree recognized by the NMC
(II) JIPMER M.D/DNB in General Medicine/Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(III) PGIMER MD in Medicine or equivalent
29. DM-NEURO-ANAESTHESIOLOGY & CRITICAL CARE/DM-NEURO ANAESTHESIA*/NEUROANAESTHESIA AND NEUROCRITICAL CARE**(MS0703301)
(I) AIIMS M.D/ DNB in Anaesthesiology of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER*
(III) SCTIMST*
(Iv) NIMHANS**
(v) JIPMER
30. DM-NEUROIMAGING AND INTERVENTIONAL NEURORADIOLOGY/NEUROIMAGING AND INTERVENTIONS(MS0703501)
(I) AIIMS M.D./ DNB Degree in Radio diagnosis of this Institute or any other University or equivalent degree recognized by the NMC
(II) NIMHANS
(III) JIPMER
(Iv) PGIMER M.D./DNB in Radiology or equivalent
(v) SCTIMST M.D./ DNB Degree in Radio diagnosis/Radiology of any Indian university or equivalent degree recognized by the NMC
31. DM-NEUROLOGY(MS0703401)
(I) AIIMS M.D. in Medicine/Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) JIPMER M.D. in General Medicine/Paediatrics of any Indian University or equivalent degree recognized by the NMC
(III) SCTIMST
(Iv) NIMHANS M.D./DNB in Internal (General) Medicine/Paediatrics
(v) PGIMER MD in Medicine or equivalent
32. DM-NEUROPATHOLOGY(MS0707301)
(I) NIMHANS MD/DNB in Pathology
33. DM-ONCO-ANAESTHESIA(MS0704301)
(I) AIIMS M.D/ DNB in Anaesthesiology of this Institute or any other University or equivalent degree recognized by the NMC
34. DM-PAEDIATRIC ANAESTHESIA & INTENSIVE CARE(MS0700103)
PGIMER MD Anaesthesia or equivalent
35. DM-PAEDIATRIC CARDIOLOGY(MS0700902)
(I) AIIMS M.D.in Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER
(III) SCTIMST
36. DM-PAEDIATRIC CLINICAL IMMUNOLOGY AND RHEUMATOLOGY(MS0704908)
(I) PGIMER MD Paediatrics or equivalent
37. DM- PAEDIATRIC EMERGENCY MEDICINE (MS0704912)
(I) AIIMS MD/DNB Paediatrics or Emergency Medicine recognized by Medical Council of India/NMC
38. DM-PAEDIATRIC ENDOCRINOLOGY(MS0704907)
(I) AIIMS MD Paediatrics or equivalent
(II) PGIMER
39. DM-PAEDIATRIC GASTROENTEROLOGY & HEPATOLOGY/PAEDIATRIC GASTROENTEROLOGY*(MS0707101)
(I) AIIMS MD/DNB Paediatrics or equivalent
(II) PGIMER
40. DM-PAEDIATRIC HAEMATOLOGY-ONCOLOGY(MS0704909)
(I) AIIMS MD/DNB Paediatrics or equivalent
(II) PGIMER
41. DM-PAEDIATRIC NEPHROLOGY(MS0704903)
(I) AIIMS M.D/DNB in Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER
42. DM-PAEDIATRIC NEUROLOGY(MS0704904)
(I) AIIMS M.D/DNB in Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER
43. DM-PAEDIATRIC PULMONOLOGY & INTENSIVE CARE(MS0704905)
(I) AIIMS M.D/DNB in Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC
44. DM-PAEDIATRIC PULMONOLOGY(MS0704910)
(I) AIIMS MD Paediatrics or equivalent
(II) PGIMER
45. DM-PAEDIATRICS CRITICAL CARE(MS0704911)
(I) AIIMS MD/DNB Degree in Paediatrics or equivalent
(II) PGIMER
(III) JIPMER
46. DM- PAIN MEDICINE (MS0700104)
(I) AIIMS MD(Anaesthesiology) or equivalent
47. DM-PULMONARY CRITICAL CARE & SLEEP MEDICINE(MS0705701)
(I) AIIMS M.D in Medicine/MD Pulmonary Medicine/MD Chest Medicine/MD Respiratory Medicine of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER MD Medicine/Respiratory Diseases or equivalent
48. DM-THERAPEUTIC NUCLEAR MEDICINE(MS0703802)
(I) AIIMS M.D in Nuclear Medicine of this Institute or any other University orequivalent degree recognized by the NMC
49. DM-PAEDIATRIC ANAESTHESIOLOGY (MS0704913)
(I) AIIMS MD Anaesthesiology
50. DM-VIROLOGY (MS0708201)
(I) AIIMS MD Microbiology
51. DM-GLOBAL HEALTH & CLINICAL EPIDEMIOLOGY (MS0708301)
(I) AIIMS MD in Community Medicine, Family Medicine, Paediatrics, General (Internal) Medicine, and Geriatrics Medicine of this Institute or any other University or equivalent degree recognized by the NMC
52. DM-METABOLISM MEDICINE/METABOLIC MEDICINE (MS0700301)
(I) AIIMS MD Biochemistry/MD Medicine/MD Paediatrics/MD Internal Medicine/MD CFM from an Institute recognised by MCI
53. DM-PSYCHOSOMATIC MEDICINE (MS0708401)
(I) AIIMS M.D/DNB in Psychiatry of this Institute of any other University or equivalent degree recognized by the NMC.

M.Ch Courses Eligibility and Educational Qualification

54.M.Ch-BREAST, ENDOCRINE AND GENERAL SURGERY(MS0806301)
(I) AIIMS M.S. degree in Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) PGIMER MS (Surgery/General Surgery/equivalent)
55.M.Ch.- C.T.V.S/CVTS*(MS0801001)
(I) AIIMS M.S./DNB degree in Surgery/General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) JIPMER
(III) PGIMER*
(IV) SCTIMST*
56. M.CH-CORNEA, CATARACT AND REFRACTIVE SURGERY(MS0804501)
(I) AIIMS MD/MS Ophthalmology or equivalent
57. M.Ch-G.I. SURGERY/SURGICAL GASTROENTEROLOGY(MS0802301)
(I) AIIMS M.S. degree in Surgery/General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) JIPMER
(III) PGIMER
58. M.Ch-GYNAECOLOGIC ONCOLOGY(MS0804402)
(I) AIIMS MD/MS in Obstetrics & Gynaecology of this Institute or any other University or equivalent degree recognized by MCI
(II) JIPMER
59. M.CH. HAND AND MICROVASCULAR SURGERY (MS0805502)
(I) AIIMS M.S degree in General Surgery/Orthopaedics of this Institute or any other University or any other equivalent degree recognized by the NMC/MCI
60. M.Ch-HEAD-NECK SURGERY AND ONCOLOGY / HEAD & NECK SURGERY*(MS0804801)
(I) AIIMS M.S degree in Surgery/ENT of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) PGIMER*
61. M.CH. JOINT REPLACEMENT & RECONSTRUCTION(MS0804702)
(I) AIIMS MS/DNB Orthopaedics or an equivalent degree recognized by Medical Council of India/NMC.
62. M.Ch-MINIMAL ACCESS SURGERY & GENERAL SURGERY(MS0806302)
(I) AIIMS M.S. degree in Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
63. M.Ch-NEURO-SURGERY(MS0803601)
(I) AIIMS M.S./DNB degree in Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) PGIMER
(III) NIMHANS M.S./DNB degree in General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
(Iv) JIPMER
(v) SCTIMST
64. M.CH.-PAEDIATRIC ORTHOPEDICS SURGERY/ PAEDIATRIC ORTHOPEDICS(MS0804701)
(I) AIIMS* MS/DNB Orthopaedics or equivalent
(II) PGIMER
65. M. Ch.-PAEDIATRIC SURGERY(MS0805001)
(I) AIIMS M.S. degree in Surgery/General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) JIPMER
(III) PGIMER
66. M.Ch-PLASTIC AND RECONSTRUCTIVE SURGERY/PLASTIC SURGERY*(MS0805501)
(I) AIIMS M.S degree in Surgery/ENT/Orthopaedics of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) PGIMER*
(III) JIPMER M.S /DNB degree in General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
67. M.CH. -RENAL TRANSPLANT SURGERY(MS0803202)
(I) PGIMER MS Surgery or equivalent
68.M.Ch-SURGICAL ONCOLOGY(MS0806401)
(I) AIIMS M.S degree in Surgery/ENT of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) JIPMER M.S./ DNB Degree in General Surgery / Obstetrics & Gynaecology / Otorhinolaryngology (E.N.T) / Orthopaedics Surgery recognized by the MCI.
69. M.Ch-TRAUMA SURGERY AND CRITICAL CARE(MS0806701)
(I) AIIMS M.S degree in Surgery/Trauma and Emergency Surgery of this Instituteor any other University or any other equivalent degree recognized by the MCI
70.M.Ch-UROLOGY(MS0806801)
(I) AIIMS M.S. degree in Surgery/General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) PGIMER
(III) JIPMER
71. M.CH- VASCULAR SURGERY (MS0808101)
(I) SCTIMST MS/DNB in Gen. Surgery/Equivalent degree recognized by NMC
72. M.Ch- SPORTS INJURY (MS0806702)
(I) AIIMS M.S Orthopaedics /DNB Orthopaedics from any recognized institution

Powered by WPeMatico

UNFPA Commends India’s monumental efforts in reducing MMR by 70% between 2000 and 2020

New Delhi: The United Nations Population Fund (UNFPA) has recognized India’s extraordinary progress in advancing Maternal Health and Family Planning. 

Dr Natalia Kanem, Executive Director of UNFPA, felicitated Smt. Punya Salila Srivastava, Union Health Secretary, by presenting a plaque and certificate and underlined UNFPA’s unwavering commitment to partnering with India toward women’s health and well-being.

The Ministry of Health and Family Welfare is implementing a number of programmes to improve maternal health outcomes toward achieving zero preventable maternal deaths. These include assured quality and respectful maternity care under the Surakshit Matritva Aashwasan Yojana (SUMAN), Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA) and the Midwifery Services Initiative.

Also Read:India’s Maternal Mortality Ratio improves by 6 points, achieves National Health Policy target

In the presence of Smt. Aradhana Patnaik, Additional Secretary and Mission Director, National Health Mission; Smt. Meera Srivastava, Joint Secretary, Reproductive & Child Health (RCH); Mr. Pio Smith, Asia Pacific Regional Director for UNFPA; and Ms. Andrea M. Wojnar, UNFPA India Representative, Dr. Kanem commended India’s monumental efforts in reducing the Maternal Mortality Ratio (MMR) by an impressive 70% between 2000 and 2020, positioning the country to achieve the Sustainable Development Goal (SDG) target of an MMR below 70 before 2030. This remarkable progress has saved the lives of thousands of women across the country, particularly those from marginalized communities.

India’s Family Planning program has reached new heights, with the Total Fertility Rate reduced below the replacement level (TFR-2). Over the years, UNFPA has played a key role in expanding the basket of contraceptive choices, including the recent inclusion of Subdermal Implants and injectable Depot Medroxyprogesterone Acetate (DMPA).

The Ministry’s leadership in global reproductive health forums was acknowledged with India holding key positions in the Partnership for Maternal, Newborn & Child Health (PMNCH) and the Family Planning 2030 (FP2030) global partnership.

During the meeting, Dr. Kanem reaffirmed UNFPA’s steadfast commitment to supporting India’s efforts in advancing the health and well-being of women, girls, and young people.

As UNFPA commemorates 50 years of partnership with the Government of India, this event marks a significant moment in their shared mission to ensure the health and well-being of every woman and young person in India as the nation progresses toward the vision of ‘Viksit Bharat’.

Dr Indu Grewal, Additional Commissioner (Family Planning/Pre-Conception and Pre-Natal Diagnostic Techniques/ABP), Dr Pawan Kumar, Additional Commissioner (Maternal Health & Immunization), Dr Zoya Ali Rizvi, Deputy Commissioner (Nutrition & Adolescent Health), delegates from UNFPA and other senior officials from the Ministry were also present at the event.

Also Read:Maternal mortality ratio declines by 8.8 percent, says govt

Powered by WPeMatico

FDA Approves New new treatment option for cutting bleeding in Hemophilia A or B

Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII (FVIII) or IX (FIX), respectively. Patients with these hemophilias are unable to clot properly and may bleed for a longer time than normal after injury or surgery.

The U.S. Food and Drug Administration has approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies).

The FDA  has granted the approval of Hympavzi to Pfizer Inc. Earlier the FDA  had granted Hympavzi Orphan Drug designation for this application.

“Today’s approval of Hympavzi provides patients with hemophilia a new treatment option that is the first of its kind to work by targeting a protein in the blood clotting process,” said Ann Farrell, M.D., Director of the Division of Non-Malignant Hematology in the FDA’s Center for Drug Evaluation and Research. “This new type of treatment underscores the FDA’s commitment to advance the development of innovative, safe and effective therapies.”

Hympavzi is a new type of drug that, rather than replacing a clotting factor, works by reducing the amount, and therefore, the activity of, the naturally occurring anticoagulation protein called tissue factor pathway inhibitor. This increases the amount of thrombin, an enzyme that is critical in blood clotting, that is generated. This is expected to reduce or prevent the frequency of bleeding episodes.

Hympavzi’s approval is based on an open-label, multi-center study in 116 adult and pediatric male patients with either severe hemophilia A or severe hemophilia B, both without inhibitors. For the first six months of this study, patients received treatment with replacement factor either on-demand (33 patients) or prophylactically (83 patients). These patients then received Hympavzi prophylaxis for 12 months. The primary measure of efficacy of Hympavzi was the annualized bleeding rates of treated bleeds. In the patients receiving on-demand factor replacement during the first six months of the study, the estimated annualized bleeding rate was 38 compared to the estimated annualized bleeding rate during treatment with Hympavzi of 3.2, showing that Hympavzi was superior to on-demand factor replacement. In the initial six-month period during which patients received prophylactic factor replacement, the estimated annualized bleeding rate was 7.85 and was 5.08 during the subsequent 12 months on Hympavzi prophylaxis, showing that Hympavzi provided similar bleeding rates.

Hympavzi comes with warnings and precautions about circulating blood clots (thromboembolic events), hypersensitivity and embryofetal toxicity.

The most common side effects of Hympavzi are injection site reactions, headache and itching (pruritis).

Powered by WPeMatico